Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators
- PMID: 17010675
- DOI: 10.1016/j.ccr.2006.09.005
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators
Abstract
Although androgen receptor (AR)-mediated signaling is central to prostate cancer, the ability to modulate AR signaling states is limited. Here we establish a chemical genomic approach for discovery and target prediction of modulators of cancer phenotypes, as exemplified by AR signaling. We first identify AR activation inhibitors, including a group of structurally related compounds comprising celastrol, gedunin, and derivatives. To develop an in silico approach for target pathway identification, we apply a gene expression-based analysis that classifies HSP90 inhibitors as having similar activity to celastrol and gedunin. Validating this prediction, we demonstrate that celastrol and gedunin inhibit HSP90 activity and HSP90 clients, including AR. Broadly, this work identifies new modes of HSP90 modulation through a gene expression-based strategy.
Comment in
-
Accelerating drug discovery: Open source cancer cell biology?Cancer Cell. 2006 Nov;10(5):349-51. doi: 10.1016/j.ccr.2006.10.011. Cancer Cell. 2006. PMID: 17097556
Similar articles
-
Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.Endocr Relat Cancer. 2015 Oct;22(5):805-18. doi: 10.1530/ERC-14-0541. Epub 2015 Jul 17. Endocr Relat Cancer. 2015. PMID: 26187127
-
Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.Int J Urol. 2010 Mar;17(3):281-5. doi: 10.1111/j.1442-2042.2010.02450.x. Int J Urol. 2010. PMID: 20409220
-
The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.Prostate. 2007 Apr 1;67(5):509-20. doi: 10.1002/pros.20541. Prostate. 2007. PMID: 17221841 Free PMC article.
-
Hsp90 as a therapeutic target in prostate cancer.Semin Oncol. 2003 Oct;30(5):709-16. doi: 10.1016/s0093-7754(03)00346-4. Semin Oncol. 2003. PMID: 14571418 Review.
-
Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.Curr Med Chem. 2007;14(29):3122-38. doi: 10.2174/092986707782793925. Curr Med Chem. 2007. PMID: 18220746 Review.
Cited by
-
Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer.Clin Pharmacol Ther. 2022 Jun;111(6):1296-1306. doi: 10.1002/cpt.2582. Epub 2022 Apr 12. Clin Pharmacol Ther. 2022. PMID: 35288936 Free PMC article.
-
Computational analyses of mechanism of action (MoA): data, methods and integration.RSC Chem Biol. 2021 Dec 22;3(2):170-200. doi: 10.1039/d1cb00069a. eCollection 2022 Feb 9. RSC Chem Biol. 2021. PMID: 35360890 Free PMC article. Review.
-
Grand challenge commentary: Chemical transdifferentiation and regenerative medicine.Nat Chem Biol. 2010 Dec;6(12):877-9. doi: 10.1038/nchembio.472. Nat Chem Biol. 2010. PMID: 21079596
-
A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer.Ann Transl Med. 2021 Dec;9(24):1782. doi: 10.21037/atm-21-6191. Ann Transl Med. 2021. PMID: 35071476 Free PMC article.
-
Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule.Mol Biol Cell. 2008 Mar;19(3):1104-12. doi: 10.1091/mbc.e07-10-1004. Epub 2008 Jan 16. Mol Biol Cell. 2008. PMID: 18199679 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous